Sichuan Kelun-Biotech Biopharmaceutical
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is a Chinese biopharmaceutical company engaged in the discovery, development, and commercialization of novel oncology therapies. The company specializes in antibody-drug conjugates, monoclonal antibodies, and targeted small molecule therapies for advanced solid tumors and hematological malignancies. Its core pipeline features sacituzumab tirumotecan and multiple clinical-stage antibody-drug conjugate candidates designed to target specific cancer cell antigens. Principal revenue is derived from milestone payments, upfront licensing fees from international biopharmaceutical partnerships, research collaborations, and commercial sales of approved oncology products in China. Kelun-Biotech is recognized as a global innovator in antibody-drug conjugate technology, holding strategic licensing partnerships with major pharmaceutical corporations like Merck & Co. Headquartered in Chengdu, China, the company's common shares are publicly traded on the Hong Kong Stock Exchange under the ticker 6990.
15 of the funds FundTelligence covers report a position in Sichuan Kelun-Biotech Biopharmaceutical.
- Legal name
- Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd.
- Sector
- Health Care
- Country
- China
- Funds holding it
- 15
Funds holding Sichuan Kelun-Biotech Biopharmaceutical
- DNB Fund Asian Mid Cap — DNB · 1.45 % (full portfolio disclosed, September 2026)
- Handelsbanken Vekstmarked Tema — Handelsbanken · 0.47 % (full portfolio disclosed, September 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.39 % (full portfolio disclosed, October 2026)
- Handelsbanken Helse Tema — Handelsbanken · 0.36 % (full portfolio disclosed, October 2026)
- Storebrand Indeks Nye Markeder — Storebrand · 0.03 % (full portfolio disclosed, October 2026)
- DNB Emerging Markets Index — DNB · 0.03 % (full portfolio disclosed, September 2026)
- Storebrand Emerging Markets — Storebrand · 0.03 % (full portfolio disclosed, October 2026)
- KLP AksjeFremvoksende Markeder Indeks — KLP · 0.03 % (full portfolio disclosed, June 2026)
Showing the 8 largest of 15 funds holding it.